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The present study investigated promoter hypermethylation of TP53 regulatory pathways providing a potential
link between epigenetic changes and mitochondrial DNA (mtDNA) alterations in breast cancer patients lack-
ing a TP53 mutation. The possibility of using the cancer-specific alterations in serum samples as a blood-
based test was also explored. Triple-matched samples (cancerous tissues, matched adjacent normal tissues
and serum samples) from breast cancer patients were screened for TP53mutations, and the promoter methyl-
ation profile of P14ARF, MDM2, TP53 and PTEN genes was analyzed as well as mtDNA alterations, including
D-loop mutations and mtDNA content. In the studied cohort, no mutation was found in TP53 (DNA-binding
domain). Comparison of P14ARF and PTEN methylation patterns showed significant hypermethylation
levels in tumor tissues (P < 0.05 and <0.01, respectively) whereas the TP53 tumor suppressor gene was
not hypermethylated (P < 0.511). The proportion of PTEN methylation was significantly higher in serum
than in the normal tissues and it has a significant correlation to tumor tissues (P < 0.05). mtDNA analysis
revealed 36.36% somatic and 90.91% germline mutations in the D-loop region and also significant mtDNA
depletion in tumor tissues (P < 0.01). In addition, the mtDNA content in matched serum was significantly
lower than in the normal tissues (P < 0.05). These data can provide an insight into the management of a thera-
peutic approach based on the reversal of epigenetic silencing of the crucial genes involved in regulatory
pathways of the tumor suppressor TP53. Additionally, release of significant aberrant methylated PTEN in
matched serum samples might represent a promising biomarker for breast cancer.
INTRODUCTION
Breast cancer is the most common malignancy among females
worldwide. A large number of reports have discussed the impor-
tant role of TP53 alterations in breast cancer. The TP53 tumor
suppressor gene has a central role in cell cycle regulation (1),
DNA repair (2,3), senescence and apoptosis (4), differentiation
and development, and prevention of cancer (5).
Recent studies showed that the TP53 gene contributes to tran-
scription or replication regulatory mechanisms of mitochondria
and also boosts mitochondrial genomic stability via stimulation
of base excision repair (6–8). Human mitochondrial DNA
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(mtDNA) mutation can be induced by generation of reactive
oxygen species (ROS). An increase of mtDNA sensitivity to
DNA-damaging oxidative stress such as ROS has been shown
to result via deregulation of p53 protein in cancer cells (8,9).
Most of the mtDNA mutations occur in the D-loop region, the
major replication and transcription site of both the heavy and
light strands of mtDNA (10–12). Previous studies in this area
showed that somatic mutation in the DNA-binding domain of
the TP53 gene contributes to mtDNA mutation and mtDNA
depletion that indicates a possible role in tumorigenesis of
breast cancer patients (8,13,14).
Deregulation of the tumor suppressor TP53 gene during
pathogenesis of most human cancers has been reported via
mutation or through alteration in encoding regulators of
TP53 (15–17). The frequency of TP53 mutations detected in
breast cancer is 20% that were mostly determined by
sequence analysis of the DNA-binding domain (exons 5–8)
(18,19). This frequency is lower than that of many other
cancers. Other than TP53 mutation, alteration of upstream
and/or downstream TP53 regulators could be another plausible
mechanism for inactivation and suppression of this gene in
breast cancer. Recently, association of promoter hypermethy-
lation with mtDNA alteration and nuclear DNA crosstalk has
been reported in cancer (20). Taken together, this can provide
new insights into epigenetic silencing of some of the regulat-
ory pathways, leading to the deregulation of p53 protein which
most probably influences the mtDNA vulnerability in breast
cancers lacking TP53 mutation. The P14ARF/MDM2/TP53
and PTEN pathways are the two critical TP53 control path-
ways, and alteration of either pathway can induce a variety
of cancers and they are thus the focus of many breast cancer
investigations (5,21–25).
Regarding the P14ARF/MDM2/TP53 pathway, Mdm2 nor-
mally inactivates the tumor suppressor TP53 and, in response
to stress, regulates the duration and activity of p53 protein.
Mdm2 protein binds directly to TP53 to inhibit transcription
and export p53 from the nucleolus to the cytoplasm, resulting
in the degradation of p53 by ubiquitination (26,27). The role of
p14ARF in the TP53 pathway is to indirectly regulate the level
of p53 protein. p14ARF protein inhibits degradation of p53
protein by keeping Mdm2 in the nucleolus and also restricting
E3 ubiquitin protein (26).
Phosphatase and tensin homolog deleted on chromosome 10
(PTEN) is an essential component of the TP53 gene response
upon DNA damage. Pten protein indirectly regulates p53 func-
tion through keeping Akt inactive and making Mdm2 incap-
able of translocating into the cell nucleus for degradation of
p53 (28,29). Indeed, Pten protects p53 even in the presence
of Mdm2 by increasing p53-mediated transcription (28) as
well as binding to p53, leading to an increase in the half-life
of p53 (30).
The aim of the present study was to investigate the promoter
methylation profile of the regulatory pathways of TP53
(P14ARF/MDM2/TP53, as well as PTEN), providing the poten-
tial link between epigenetic changes and mtDNA alteration
in tumorigenesis in breast cancer patients lacking TP53
mutation on the DNA-binding domain. The pathway analysis
was performed to verify which of the selected genes were
most relevant in breast cancer. Triple-matched samples from
breast cancer patients (cancerous tissues, matched normal
tissues and serum samples) were subjected to mutation analy-
sis of the DNA-binding domain of TP53, assessment of the
promoter methylation profile of four candidate genes
(P14ARF/MDM2/TP53/PTEN) and mtDNA alteration, includ-
ing D-loop region integrity and mtDNA content to measure
the correlation of the aforementioned subjects in the studied
cohort. This approach presented the cancer-specific alterations
in tissues followed by exploration of the possibility of using
the alterations in corresponding serum samples as a blood-
based test.
RESULTS
P14ARF/MDM2/TP53 and PTEN pathway analysis
First, the network of the candidate genes was analyzed as a
function of cellular interactions and breast cancer develop-
ment. The direct interaction pathway analysis displayed
specific upstream and downstream of four candidate genes
that identify common targets and regulators for these genes.
Additionally, it showed the binding partner of these genes
and behaving role in breast cancer (Fig. 1). Signaling analysis
including hierarchical and direct force analysis are shown in
Supplementary Material 1. This analysis provided an approach
to compare different kinds of interactions, including protein–
protein interactions as well as genetic interaction.
TP53 mutation screening
The analysis of the results after direct sequencing of exons 5–8
of the TP53 gene revealed no mutation in the 44 normal and can-
cerous breast tissue samples from 22 patients compared with the
TP53 GenBank sequence (NC_000017 [gi:224589808]).
Quantitative methylation profiles of P14ARF/MDM2/TP53
and the PTEN promoter using MALDI-TOF MS
In this study, we analyzed the methylation patterns of four
breast cancer candidate genes in 66 triple-matched samples
(cancerous tissues, matched normal tissues and serum
samples) from 22 breast cancer patients. For all the genes,
1 amplicon per gene and 117 CpG sites in total per sample
(total of 7020 sites in 66 analyzed samples) were analyzed
(Table 1; Supplementary Material 3). In the present study, a
low degree of methylation with mean methylation levels
,30% was considered as hypomethylation and a high
degree of methylation with mean methylation levels .70%
was considered as hypermethylation.
Using two-way hierarchical cluster analysis, we found differ-
ent levels of methylation between tumor tissue, the matched
serum and the normal tissue samples. The methylation quantifi-
cation data for each studied gene are illustrated in Supplemen-
tary Material 3. The methylation alteration level of the
individual CpG sites or clusters per gene showed a variable
signature in the studied cases (Supplementary Material 3); the
mean methylation quantity of the informative CpG sites that
represent valuable differences in each case was used to figure
out the promoter alterations in the candidate genes. Hierarchical
cluster analysis profiling of the promoter alterations of the four
studied genes is shown in Figure 2A.
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The MDM2 oncogene for both the tumor and normal tissues
showed a relatively comparable hypomethylation pattern
whereas matched serum was significantly different compared
with normal tissue (P , 0.05). Evaluation of the methylation
proportion of P14ARF presented significant hypermethylation
in tumor tissue versus normal tissue and in matched serum
versus tumor tissue (P , 0.05 and ,0.01, respectively). Com-
parison of the PTEN methylation pattern showed significantly
higher hypermethylation levels in tumor tissue and matched
serum than the normal tissue (P, 0.01 and ,0.05, respect-
ively). Our data showed significant concordance between the
tumor and serum PTEN methylation profile (Spearman’s rho
test; P , 0.05). Methylation analysis of TP53 showed no sig-
nificant differences between tumor tissue and matched serum
versus normal tissue whereas matched serum and tumor
tissue revealed significant difference (P ¼ 0.01; Fig. 2B).
Schematic comparison of methylation rate of analyzed
genes with upstream regulatory sequence
The methylation rate and localization of each CpG site were
compared with upstream sites for regulatory enhancers,
CAAT box, GC box, transcription factor IIB recognition
elements, TATA box, initiation site of transcription and down-
stream promoter elements. Figure 2C schematically compares
the upstream regulatory sequences (in the range of 21000 to
+100) with the methylation value of informative CpG sites of
Figure 1. Direct interaction pathway analysis of four candidate genes related to breast cancer.
Table 1. High-throughput methylation analysis of CpG sites in the amplicons
of the studied genes in breast cancer
Gene Amplicon
size (bp)
Total no. of
CpG sites in
amplicon
No. of
analyzed
CpG sites in
amplicon
No. of analyzed CpG
sites per amplicon
Single
sites
Composite
sites
MDM2 303 39 27 7 20
P14ARF 425 36 26 6 20
PTEN 451 34 29 10 19
TP53 449 39 35 17 18
The in silico digestion was performed for the T-cleavage assay. The percentage
of total CpG sites in the amplicon is divided into single sites (single CpG sites)
and composite sites (two or more adjacent CpG sites fall within one fragment,
or when fragment masses are overlapping).
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the four studied genes together. Accumulation of some hyper-
methylated CpG sites around the TATA box region was
observed for tumor-derived samples. In serum and normal
samples, the CpG sites were differentially methylated and
located randomly in the 5′-UTRs of the studied genes
(Fig. 2C).
D-loop region mutation screening
The results of the D-loop region after direct sequencing in a
pair study of normal tissue versus tumor were analyzed and
compared with the human mitochondrial sequence (GenBank
sequence NC_012920 [gi:251831106]). D-loop region
mutation screening showed somatic mutations in 36.36% (8
of 22) of studied cancerous samples. Six of the eight cases
showed a single somatic mutation, whereas of the remainder
one had 2 and the other had 7 somatic mutations. The
prevalence of detected germline mutations in the D-loop
region was markedly higher at 90.91% (20 of 22) than
somatic mutations and with mostly multiple germline
mutations in each case. A total of 82 mutations were detected
in the D-loop region of the studied samples, including 15
Figure 2. (A) Double dendrogram presents the methylation profiles of the four studied genes in triple-matched samples from 22 breast cancer patients (red clus-
ters indicate 0% methylated, yellow clusters indicate 100% methylated, color gradient between red and yellow indicates methylation ranging from 0 to 100).
(B) Comparison between quantitative analysis of methylation for the studied genes in triple-matched samples (∗significant correlation; Mann–Whitney
U-test). (C) Comparison of the methylation ratio and approximate position of informative CpG sites of the four studied genes according to the recognition
sites of the transcription factors (in the range of 21000 to +100) in the triple-matched samples. (Each dot in the map corresponds to the mean amount of
CpG site methylation in all cases of each studied group.) (D) Correlation study between methylation quantity, D-loop mutations and mtDNA content.
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somatic mutations and 67 germline mutations. The details of
the prevalence of germline and somatic mutations are pro-
vided in Table 2, and the spectrum of the mutation along the
length of the D-loop is illustrated in Figure 3.
Mitochondrial content in triple-matched samples
The mtDNA contents of the studied, cancerous and normal
breast tissue, as well as serum samples were measured using
multiplex quantitative real-time PCR. The mtDNA content
results obtained from cancer tissues were significantly lower
than that of the normal tissues, with 11.88-fold changes
(P, 0.01). Nineteen of 22 cancer tissues compared with
normal tissues had lower mtDNA content (86.36%). The
content of mtDNA in matched serum was lower than in
normal and cancer tissues. The mtDNA content of matched
serum was significantly lower than that of normal tissues
(Spearman’s rho test; P,0.05; Fig. 4).
Relationship of TP53/P14/MDM2 and PTEN methylation
profile, mtDNA alteration and clinicopathological
parameters
The correlation of the methylation proportion of the studied
genes to mtDNA alteration (D-loop mutations and mtDNA
content) is summarized in Figure 2D. A negative correlation
between germline mutation number and MDM2, as well as
P14ARF methylation profile in tumor tissues has been found
(Spearman’s rho test; P , 0.05).
The mtDNA content showed no difference between patients
with and without D-loop region mutations, suggesting that the
mtDNA depletion may not be a result of the mutations
(Fig. 4).
Clinicopathological parameters with our findings were ana-
lyzed (Supplementary Material 4). Breast cancer patients with
the ILC histological type showed significant association with
somatic mutations of the D-loop region (P, 0.05). In
matched serum samples, patients with histological grade II
had a higher proportion of hypermethylation of the PTEN
gene and lower mtDNA content than histological grade III
(P , 0.05). Serum samples of patients with C-ERB2
expression showed a greater proportion of hypermentylation
of P14ARF than patients lacking C-ERB2 expression
(P , 0.05).
DISCUSSION
p53 dysfunction can be compromised by TP53 mutation,
methylation or gene alteration of crucial p53 regulators. The
majority of TP53 mutation occur in the DNA-binding
domain (exons 5–8); this domain has a critical role for the bio-
logical activity of p53 (31). The TP53 mutation occurs in
approximately 20% of breast cancer cases (19), and this fre-
quency is lower than that of the other types of cancer. In the
present study, the results showed no mutation in the TP53
gene (DNA-binding domain) of the studied cohort, thus
these samples were subjected to further epigenetic analysis.
Apart from TP53 mutation, alteration of upstream and/or
downstream regulatory factors could be another plausible
mechanism for TP53 inactivation and suppression in breast
cancer. To find the molecular mechanism involved in tumor
suppressor p53 protein deregulation of breast cancer patients
lacking TP53 mutation, we assessed epigenetic alteration of
P14ARF/MDM2/TP53 and PTEN, important regulatory path-
ways of p53. Aberrant methylation of CpG islands is the
most common alteration in human cancer (33). In the
present study, the promoter methylation profile of four candi-
date genes, P14ARF, MDM2, TP53 and PTEN, was analyzed in
66 samples (breast tumors, matched normal tissue and serum
samples). In tumor tissue, the MDM2 oncogene showed hyper-
methylation patterns comparable with normal tissues. Com-
parison of P14ARF and PTEN methylation patterns showed
significant hypermethylation levels in tumor tissues when
compared with the normal tissues (P , 0.05 and ,0.01,
respectively) while the TP53 tumor suppressor gene was not
hypermethylated. Additionally, significant accumulation of
hypermethylated CpG sites in the promoter region was
observed for tumor tissues, which might suggest prevention
of RNA polymerase action at transcriptional promoter
Table 2. Summary of the D-loop mutations found in breast cancer patients
D-loop alteration Mutation name Mutation frequency (%)
Somatic 64 C. C/T (H) 1 (4.54)
146 T. C 1 (4.54)
152 T. C 1 (4.54)
199 T. C 1 (4.54)
235 A. G 1 (4.54)
256 C. G 1 (4.54)
257 A. G 1 (4.54)
16290 C. T 1 (4.54)
16291 C. T 1 (4.54)
16311 T . C 2 (9.09)
16319 G . A 2 (9.09)
16389 G . G/C (H) 1 (4.54)
16519 T . C 1 (4.54)
Germline 41 C. C/T (H) 1 (4.54)
83 A . A/C (H) 1 (4.54)
84 A . A/C (H) 1 (4.54)
146 T. C 3 (13.64)
150 C. T 3 (13.64)
152 T. C 1 (4.54)
199 T. C 1 (4.54)
204 T. C 2 (9.09)
207 G. A 3 (13.64)
210 A. G 1 (4.54)
235 A. G 2 (9.09)
248 Del A 1 (4.54)
297 A. C/A (H) 2 (9.09)
390 A. G 1 (4.54)
398 C. T 1 (4.54)
489 T. C 4 (18.18)
16278 C. T 2 (9.09)
16290 C. T 3 (13.64)
16291 C. T 1 (4.54)
16304 T . C 2 (9.09)
16311 T . C 4 (18.18)
16317 A . G 1 (4.54)
16319 G . A 3 (13.64)
16357 T . C 1 (4.54)
16362 T . C 11 (50)
16438 G . A 1 (4.54)
16497 A . G 1 (4.54)
16519 T . C 8 (36.36)
H, heterozygosity; Del, nucleotide deletion.
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regions of P14ARF and PTEN tumor suppressor genes leading
to gene silencing. These results are in line with recent reports
based upon methylation status and aberrant expression. Pre-
vious studies have investigated frequent aberrant methylation
patterns of P14ARF and a down-regulation of this tumor sup-
pressor gene in breast tumors (21,34). Hypermethylation of
the promoter of PTEN has also been found in breast carcinoma
that led to PTEN inactivation in a subset of breast cancers
(35–37).
Pathway analysis served as the important step toward an
improved understanding of the relationship of studied genes
in breast cancer. This investigation suggests the possibility
of p53 deregulation probably by loss of P14ARF and PTEN
or by overexpression of MDM2. Mdm2 is responsible for inac-
tivation of tumor suppressor TP53 by inhibition of transcrip-
tion and export of p53 from the nucleolus to the cytoplasm,
resulting in the degradation of p53 by ubiquitination (26,27).
Overexpression of the MDM2 gene can result in an excessive
inactivation of p53 and has been reported in 73% of breast car-
cinomas (22,23). p14ARF protein, by keeping Mdm2 in the
nucleolus and also restricting E3 ubiquitin protein, inhibits
degradation of p53 (26). Indirect activation of p53 by
p14ARF inhibits growth of abnormal cells and prevents
cancer (38). Indeed, p53 by binding to the PTEN promoter
Figure 3. Distribution of the mutations in the D-loop region and mtDNA content. The asterisk indicates the median of mtDNA content of the patients who have
the mutation in the same corresponding locus.
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leads to a positive feedback loop that decreases AKT activity
by Pten and as a result inactivates Mdm2 and protects p53
from deregulation (39). Furthermore, Pten protein protects
p53, even in the presence of Mdm2, by increasing
TP53-mediated transcription (28) and also by binding to
p53, leading to an increased p53 half-life (30). These findings
emphasize the importance of an epigenetic alteration-mediated
silencing of the tumor suppressor candidate genes and suggest
that alteration of these genes could be a cause of p53 deregu-
lation. These pathways might be targets for therapeutic strat-
egies based on reversal of epigenetic silencing in breast
cancer.
To determine the mechanistic link between inactivated
tumor suppressor p53 through epigenetic silencing regulatory
pathways and mtDNA alteration in cancer kinetics, we
assessed mtDNA damage including D-loop region integrity
and mtDNA content in breast cancer patients lacking TP53
mutation. mtDNA has a higher mutation rate than nuclear
DNA, due to its closeness to the respiratory chain, lack of
histone protein and imitated DNA repair capacity. Most of
the mutations occur in the D-loop, a major control site of repli-
cation and transcription for both the heavy and light strands of
mtDNA (10–12). Association of TP53 alteration with mtDNA
damage has been reported in a breast cancer patient (13). Our
data present a high rate of D-loop region mutations (36.36%
somatic and 90.91% germline mutations) in breast cancer
patients.
Depletion of mtDNA content has been investigated in breast
cancer and it has been attempted to correlate this to mtDNA
somatic mutation (18,40–43). The present data showed a sig-
nificant mtDNA depletion in tumor tissues compared with
normal tissues (P, 0.01). It has been demonstrated that the
depletion of mtDNA resulted from a loss of p53 function
(8). The mtDNA damage in the studied cohort, D-loop
mutations and mtDNA depletion, might be explained by the
indirect effect of p53 inactivation on mtDNA vulnerability.
Additionally, we found an inverse correlation between germ-
line mutations and MDM2 and P14ARF hypermethylation in
tumor tissues which might suggest a susceptibility to p53 inac-
tivation in breast cancer patients with a background of D-loop
mutations. Furthermore, breast cancer patients with the ILC
histological type showed a significant association with
somatic mutations of the D-loop region (P, 0.05).
Comparison of clinicopathological parameters with tumor-
specific methylation changes and mtDNA content did not
reveal additional information, and this remains to be deter-
mined in a larger cohort.
In the present study, in order to find cancer-specific markers
in tissues for the development of a blood-based test, we
assessed epigenetic alterations and mtDNA changes in
matched serum samples of the studied cohort. Epigenetic
alterations in serum of different cancers have been reported
(44–49). DNA from solid tumors are released into the sys-
temic circulation most probably through cellular necrosis or
apoptosis (50). The present study investigated the proportion
of methylation of four candidate genes in serum samples.
The P14ARF tumor suppressor genes showed higher hyper-
methylation levels than the normal tissues, though this failed
to reach the statistical significance. The hypermethylation
level of P14ARF in serum samples was lower than in tumor
tissues; this trend has also been reported previously (34).
The proportion of PTEN methylation was significantly
higher in matched serum than in the normal tissues, with a sig-
nificant concordance between the tumor and serum PTEN
methylation profile (P, 0.05), suggesting a possible use of
the marker for the development of a blood-based test with
the goal of patient management. Assessment of mtDNA
content revealed depletion of mtDNA in matched serum
versus control tissues (P , 0.05). Using mtDNA depletion
as a blood-based test, a biomarker for breast cancer patients
was suggested in a previous publication (42). Release of sig-
nificant aberrant methylated PTEN in blood might represent
Figure 4. MtDNA content. (A) Comparison between mtDNA content in tumor and adjacent normal tissues. (B) Correlation of mtDNA content in serum versus
tumor and normal samples. (∗ significant correlation; Mann–Whitney U-test).
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a promising biomarker for breast cancer with ease of access to
methylation analysis.
In conclusion, the obtained results from breast cancer
patients suggest hypermethylation of P14ARF and PTEN
could break down the P14ARF/MDM2/TP53 and PTEN regu-
latory pathways, resulting in p53 inactivation in breast
cancer patients lacking TP53 mutation in the DNA-binding
domain. Moreover, mtDNA damage can be affected by p53
deregulated through epigenetic silencing of the studied path-
ways. These data can provide an insight into the management
of a therapeutic approach based on reversal of epigenetic
silencing of the crucial genes involved in regulatory pathways
of the TP53 tumor suppressor gene. Additionally, release of
significant aberrant methylated PTEN in matched serum
samples might represent a promising biomarker for breast
cancer with ease of access to analysis.
MATERIALS AND METHODS
P14ARF/MDM2/TP53 and PTEN pathway analysis
Pathway analysis was accessed by Pathway Studiow software
program version 7 and the ResNetw 7 (Mammal) database
(Ariadne Genomics, Inc., Rockville, USA). Four candidate
genes (P14ARF, MDM2, TP53 and PTEN) were analyzed in
depth by this software to increase the biological perspective
of this study and facilitate the understanding beyond their
functional link to breast neoplasm (Fig. 1, Supplementary
Material 1).
Sampling and pathological classification
DNA was isolated from 66 triple-matched samples (cancerous
tissues, matched adjacent normal tissues and serum samples)
from 22 breast cancer patients according to the standardized
protocol as described previously (51,52). The study was
approved by the local institutional review board (Ethic com-
mission beider Basel and Sichuan University China). Written
consent forms were collected from all patients who were
involved in this study. All the blood samples were collected
before delivering any therapeutic treatments.
Staging and grading was evaluated according to the WHO
histological classification. According to pathological tumor
type and immunohistochemistry staining, we separated our
patient samples into two subgroups: invasive ductal carcinoma
(IDC) and Infiltrating Lobular Carcinoma (ILC). Breast cancer
characteristics, such as staging, histological grading and
hormone receptor expression, of the patients are listed in
Table 3.
Mutation analysis of TP53
Screening of TP53 mutation has been performed on the DNA-
binding domain (exons 5–8). Information on the primer
sequences and PCR conditions used for sequence analysis
are listed in Supplementary Material 2. Direct DNA sequen-
cing was performed by using a Big Dye terminator v3.1
cycle sequencing kit and an automated sequencer (ABI
3130, Applied Biosystem). The results of DNA sequence
analysis were compared with the reference sequences of T
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GenBank (www.ncbi.nlm.mih.gov/nucleotide) using
DNASTAR sequence alignment software (DNASTAR Laser-
gene 8, Inc., Madison, USA). All sequencing reactions were
performed in both directions and confirmed for concordance.
Methylation analysis of P14ARF/MDM2/TP53 and PTEN
pathways using thymidine-specific cleavage mass array
on MALDI-TOF MS
The SEQUENOM’s EpiTYPERTM assay is a methylation
quantification method which relies on matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS) (53). In the current report, this assay
was used to quantify the methylation of TP53, P14ARF,
MDM2 and PTEN promoter regions.
The robustness of this approach for DNA methylation
quantification has been confirmed by previous studies (32,52).
Bisulfite treatment. Bisulfite conversion of the target
sequences was performed according to the instructions of a
commercial Epitectw Bisulfite kit (QIAGEN AG, Basel,
Switzerland).
Primer designing and PCR tagging for EpiTYPERTM assay.
To design PCR primer for the candidate genes, CpG density
and CpG sites of four target sequences were analyzed.
Primer pairs have been designed to cover the promoter
regions with the most CpG sites using MethPrimer (54). In
PCR amplification, a T7 promoter tag was added to the
reverse primer, and a 10mer tag sequence was added to the
forward primer to balance the PCR primer length. Ensuring
that PTEN primers discriminate between the gene and pseudo-
gene (psiPTEN), the reverse primer was designed in a promo-
ter region consisting of different nucleotides compared with
the psiPTEN sequence (AL356489 and AF029308) especially
at the 3′ end of the primer. The primer sequences, annealing
temperatures (Ta) and PCR conditions are described in Sup-
plementary Material 2.
In vitro transcription, T-cleavage assay and mass spec-
trometry. Unincorporated dNTPs were dephosphorylated by
adding 1.7 ml of H2O and 0.3 U of shrimp alkaline phospha-
tase (SAP; SEQUENOM, Inc., San Diego, CA, USA). The
reaction mixture was incubated at 378C for 20 min, and the
SAP was then heat inactivated for 10 min at 858C. Typically,
2 ml of the PCR were directly used as a template in a 5 ml tran-
scription reaction. Twenty units of T7 RNA polymerase and
DNA polymerase (Epicentre, Madison, WI, USA) were used
to incorporate dTTP in to the transcripts. Ribonucleotides
were used at 1 mmol/l and the dNTP substrate at 2.5 mmol/l.
In the same step, the in vitro transcription RNase A (SEQUE-
NOM) was added to cleave the in vitro transcript (T-cleavage
assay). The mixture was further diluted with H2O to a final
volume of 27 ml. Twenty-two nanoliters of cleavage reaction
were robotically dispensed (nanodispenser) onto silicon
chips preloaded with matrix (SpectroCHIP; SEQUENOM).
Mass spectra were collected using a MassARRAY Compact
MALDI-TOF (SEQUENOM) and the spectra’s methylation
proportions were generated by the Epityper software v1.0
(SEQUENOM).
mtDNA alteration analysis
Mutation analysis of the mtDNA D-loop region. Mutation in
the D-loop region of mtDNA was analyzed according to a pre-
viously published method (43). Information on primers and
PCR conditions used for sequence analysis are listed in Sup-
plementary Material 2. The results of DNA sequencing were
analyzed as described before. Nucleotide numbering was
based on the current mutation nomenclature recommendations
(www.hgvs.org/mutnomen). Somatic mutations were scored as
any difference between tumor and normal tissues. We con-
sidered this to be germline variation when it was found in
both the tumor and normal tissues but different from the
GenBank data base.
Quantity assessment of mtDNA and data collection. The
mtDNA content was measured by multiplex quantitative
PCR (q-PCR) using the mtDNA-encoded ATPase 8
(MTATP 8, starting at locus 8446) and glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH) reference gene. The effi-
ciency of the multiplex synchronized quantification of both
GAPDH and MTATP 8 was measured in the previous study
of our group using standard curves obtained by serial dilution
(40). The sequence and information on the primers and probe
for the GAPDH and MTATP 8 reference genes and the q-PCR
conditions are summarized in Supplementary Material 2.
Q-PCR was carried out using the ABI PRISM 7000
sequence detection system in 25 ml of total reaction volume
containing 7 ml of H2O, 12.5 ml of PCR Master Mix
(Applied Biosystems, Rotkreuz, Switzerland), 0.75 ml of
each of the above-mentioned 10 mM primers (Microsynth,
Balagach, Switzerland), 1 ml of a 5 mM FAM-labeled
MTATP 8 probe and 0.5 ml of a 5 mM VIC-labeled GAPDH
probe (both probes from Applied Biosystems) and for each
reaction 1 ml of DNA was added.
Each sample was measured in duplicate and one negative
control was included in every run.
Standard curves with known genomic DNA concentrations
ranging from 3.125 × 104 to 10 pg/ml with six serial dilutions
(i.e. 31 250, 6250, 1250, 250, 50 and 10 pg/ml) were per-
formed. The threshold cycle (Ct) values of GAPDH and
MTATP 8 were obtained by ABI Prism 7000 SDS software.
The standard curves had average slopes at approximately
23.3 (100% efficiency) and R2 was .0.98. The content
of mtDNA was calculated using the delta Ct (DCt) of an
average Ct of mtDNA and nDNA (DCt ¼ CtnDNA 2
CtmtDNA) in the same well as an exponent of 2 (2DCt) (55).
Statistical methods
Data analysis was performed using the SPSS software (Stat-
istical Software Package for Windows, version 17). Distri-
bution of data was analyzed by Kolmogorov–Smirnov test
that demonstrated our data set was not normally distributed
(P , 0.001). The quantitative methylation profile of the four
genes was compared between cancerous tissues, matched
normal tissues and serum samples using two-way hierarchical
cluster analysis. The most variable CpG sites for each gene
were clustered based on pair-wise Euclidean distances and a
linkage algorithm for all studied samples according to the
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previously developed method by Gene Expression Statistical
System (GESS) version 7.1.19 (NCSS, Kaysville, UT, USA)
(32,52,56) followed by Mann–Whitney U-test.
The Mann–Whitney U-test and non-parametric Spearman’s
rho test were performed to determine the significance and cor-
relation of mtDNA content analysis, D-loop mutations and
clinical–pathological parameters.
Additional information
Cell signaling and pathway analysis data are available in Sup-
plementary Material 1. The sequence of PCR primers and PCR
conditions are available in Supplementary Material 2. The
complete data for high-throughput methylation analysis of
informative CpG sites in four breast cancer-related genes,
including gene location, amplicon size and two-way hierarch-
ical cluster analysis, are shown in Supplementary Material 3.
Correlation between promoter methylation, D-loop mutations
and mtDNA content with clinical parameters is given in Sup-
plementary Material 4.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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